Theravance Biopharma Company Profile (NASDAQ:TBPH)

About Theravance Biopharma

Theravance Biopharma logoTheravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TBPH
  • CUSIP:
Key Metrics:
  • Previous Close: $32.40
  • 50 Day Moving Average: $31.48
  • 200 Day Moving Average: $30.77
  • 52-Week Range: $51,942,000.00 - $13.59
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.62
  • P/E Growth: -0.02
  • Market Cap: $1.75B
  • Outstanding Shares: 51,942,000
  • Beta: 2.48
Profitability:
  • Net Margins: -358.95%
  • Return on Equity: -61.09%
  • Return on Assets: -50.81%
Debt:
  • Current Ratio: 6.03%
  • Quick Ratio: 5.76%
Additional Links:
Companies Related to Theravance Biopharma:

Analyst Ratings

Consensus Ratings for Theravance Biopharma (NASDAQ:TBPH) (?)
Ratings Breakdown: 2 Sell Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $36.67 (8.55% upside)

Analysts' Ratings History for Theravance Biopharma (NASDAQ:TBPH)
Show:
DateFirmActionRatingPrice TargetDetails
12/21/2016Needham & Company LLCInitiated CoverageBuy$40.00View Rating Details
11/9/2016Leerink SwannReiterated RatingBuy$33.00View Rating Details
11/3/2016Piper Jaffray CompaniesInitiated CoverageOverweight$42.00View Rating Details
10/12/2016Robert W. BairdDowngradeNeutral -> Underperform$19.00 -> $24.00View Rating Details
9/19/2016GuggenheimReiterated RatingPositive$40.00View Rating Details
8/29/2016Evercore ISIInitiated CoverageBuy$41.00View Rating Details
8/3/2016Bank of America CorporationDowngradeNeutral -> UnderperformView Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Theravance Biopharma (NASDAQ:TBPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
8/8/2016Q216($1.05)($1.06)$12.73 millionViewN/AView Earnings Details
5/9/2016Q116($0.96)($1.10)$18.69 million$18.40 millionViewN/AView Earnings Details
3/9/2016Q415($1.62)($1.23)($280,000.00) million$3.90 millionViewN/AView Earnings Details
11/9/2015Q315($1.44)($1.40)$4.24 million$10.70 millionViewN/AView Earnings Details
8/10/2015Q215($1.51)($1.42)$4.25 million$7.10 millionViewListenView Earnings Details
3/10/2015Q414($1.70)($2.02)$2.01 million$1.30 millionViewN/AView Earnings Details
11/6/2014Q3 14($1.85)($1.72)ViewN/AView Earnings Details
8/14/2014($0.56)($1.83)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Theravance Biopharma (NASDAQ:TBPH)
Current Year EPS Consensus Estimate: $-3.83 EPS
Next Year EPS Consensus Estimate: $-3.92 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($1.20)($1.20)($1.20)
Q3 20161($1.01)($1.01)($1.01)
Q4 20161($1.14)($1.14)($1.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Theravance Biopharma (NASDAQ:TBPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Theravance Biopharma (NASDAQ:TBPH)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 68.01%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2016Brett K HaumannSVPSell4,491$27.99$125,703.09View SEC Filing  
8/22/2016Bradford J ShaferEVPSell49,122$27.46$1,348,890.12View SEC Filing  
8/19/2016Brett K HaumannSVPSell9,509$27.97$265,966.73View SEC Filing  
3/14/2016Plc GlaxosmithklineMajor ShareholderBuy1,301,015$23,028,000.00$29,959,773,420,000.00View SEC Filing  
10/7/2015Plc GlaxosmithklineMajor ShareholderBuy44,574$607,544.00$27,080,666,256.00View SEC Filing  
8/18/2015Burton G MalkielDirectorBuy10,000$12.92$129,200.00View SEC Filing  
8/18/2015Junning LeeVPBuy9,000$12.90$116,100.00View SEC Filing  
8/17/2015Renee D GalaCFOBuy10,000$12.18$121,800.00View SEC Filing  
8/17/2015Rick E WinninghamCEOBuy80,000$11.86$948,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Theravance Biopharma (NASDAQ:TBPH)
DateHeadline
us.rd.yahoo.com logoTheravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization (NASDAQ:TBPH)
us.rd.yahoo.com - February 17 at 7:15 PM
finance.yahoo.com logoTheravance Biopharma to Report Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017 (NASDAQ:TBPH)
finance.yahoo.com - February 16 at 7:54 PM
finance.yahoo.com logoTheravance Biopharma to Report Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017 (NASDAQ:TBPH)
finance.yahoo.com - February 16 at 7:54 PM
News IconSell-side Taking Aim at Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Aiken Advocate (NASDAQ:TBPH)
aikenadvocate.com - February 15 at 6:24 AM
finance.yahoo.com logoTheravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization (NASDAQ:TBPH)
finance.yahoo.com - February 13 at 3:36 PM
finance.yahoo.com logoTheravance's Infection Drug Vibativ Positive in TOUR Study (NASDAQ:TBPH)
finance.yahoo.com - February 3 at 6:11 AM
finance.yahoo.com logoTheravance Biopharma to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:TBPH)
finance.yahoo.com - February 3 at 6:11 AM
News IconSell-side is Weighing in on Theravance Biopharma, Inc. (NASDAQ:TBPH) Earnings - Aiken Advocate (NASDAQ:TBPH)
aikenadvocate.com - January 25 at 6:23 AM
streetinsider.com logoTheravance Biopharma (TBPH) Reports Interim Data from TOUR Study in Oral Presentation at SCCM - StreetInsider.com (NASDAQ:TBPH)
www.streetinsider.com - January 25 at 6:23 AM
streetinsider.com logoTheravance Biopharma (TBPH) Reports Interim Data from TOUR Study in Oral Presentation at SCCM (NASDAQ:TBPH)
www.streetinsider.com - January 23 at 11:13 PM
us.rd.yahoo.com logoTheravance Biopharma Reports New Data from Ongoing TOUR™ Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress (NASDAQ:TBPH)
us.rd.yahoo.com - January 23 at 11:13 PM
capitalcube.com logoTheravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : January 23, 2017 (NASDAQ:TBPH)
www.capitalcube.com - January 23 at 11:13 PM
investornewswire.com logoSentiments And Ratings Alert: Theravance Biopharma, Inc. (NASDAQ:TBPH) - Investor Newswire (NASDAQ:TBPH)
www.investornewswire.com - January 23 at 8:14 AM
News IconTheravance Biopharma Inc TBPH Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:TBPH)
www.bioportfolio.com - January 22 at 7:50 PM
capitalcube.com logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : January 20, 2017 (NASDAQ:TBPH)
www.capitalcube.com - January 21 at 3:03 AM
finance.yahoo.com logoTheravance Biopharma to Present New Data from Ongoing TOUR™ Observational Patient Registry at SCCM Critical Care Congress (NASDAQ:TBPH)
finance.yahoo.com - January 17 at 11:12 PM
finance.yahoo.com logo4:07 pm Theravance Biopharma announces that new interim data from the Co's ongoing Telavancin Observational Use Registry study will be the focus of an oral presentation at the Society of Critical Care Medicine's 46th Critical Care Congress; (NASDAQ:TBPH)
finance.yahoo.com - January 17 at 11:12 PM
News IconInstitutional Heat: Foundation Asset Management LP Holding in Theravance Biopharma INC (TBPH) Has Decreased ... - The Herald Beacon (NASDAQ:TBPH)
heraldbeacon.com - January 14 at 6:30 AM
News IconTrading Indicator Check on Theravance Biopharma Inc. (TBPH) - Wall Street Beacon (NASDAQ:TBPH)
wsbeacon.com - January 13 at 4:48 AM
marketexclusive.com logoTHERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Regulation FD Disclosure (NASDAQ:TBPH)
marketexclusive.com - January 10 at 1:08 AM
biz.yahoo.com logoTHERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:TBPH)
biz.yahoo.com - January 10 at 1:08 AM
marketexclusive.com logoAnalyst Activity – Needham & Company LLC Initiates Coverage On Theravance Biopharma (NASDAQ:TBPH) With a Buy (NASDAQ:TBPH)
marketexclusive.com - December 22 at 3:56 AM
News IconRating To Observe: Theravance Biopharma (TBPH): What Needham Is Saying; Why Has $40.0 Stock Target (NASDAQ:TBPH)
www.whatsonthorold.com - December 22 at 3:56 AM
finance.yahoo.com logoCoverage initiated on Theravance Biopharma by Needham (NASDAQ:TBPH)
finance.yahoo.com - December 22 at 3:56 AM
streetinsider.com logoTheravance Biopharma (TBPH) Notes Initiation of Phase 3 Study of Closed Triple by GlaxoSmithKline and Innoviva - StreetInsider.com (NASDAQ:TBPH)
www.streetinsider.com - December 20 at 8:21 PM
streetinsider.com logoTheravance Biopharma (TBPH) Notes Initiation of Phase 3 Study of Closed Triple by GlaxoSmithKline and Innoviva (NASDAQ:TBPH)
www.streetinsider.com - December 20 at 3:02 PM
finance.yahoo.com logoTheravance Biopharma Highlights Initiation of Phase 3 Study of the Closed Triple in Patients with Asthma by GlaxoSmithKline and Innoviva (NASDAQ:TBPH)
finance.yahoo.com - December 20 at 3:02 PM
News IconTrading Views: Checking the Numbers for Theravance Biopharma Inc. (TBPH) - Yankee Analysts (NASDAQ:TBPH)
yankeeanalysts.com - December 12 at 8:48 AM
capitalcube.com logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : December 12, 2016 (NASDAQ:TBPH)
www.capitalcube.com - December 12 at 8:48 AM
News IconWatching the Technicals on Shares of Theravance Biopharma Inc. (TBPH) - StockTalk Daily (NASDAQ:TBPH)
stocktalkdaily.com - December 9 at 8:02 PM
insidermonkey.com logoIs Theravance Biopharma Inc (TBPH) A Good Stock To Buy? - Insider Monkey (blog) (NASDAQ:TBPH)
www.insidermonkey.com - December 9 at 8:02 PM
zacks.com logoTheravance Stock Up on Fast Track Status for Velusetrag (NASDAQ:TBPH)
www.zacks.com - December 7 at 8:18 AM
proactiveinvestors.co.uk logoTheravance Biopharma's stomach drug to be fast-tracked by FDA (NASDAQ:TBPH)
www.proactiveinvestors.co.uk - December 6 at 7:45 PM
streetinsider.com logoTheravance Biopharma (TBPH) Granted FDA Fast Track Status of Velusetrag for Idiopathic and Diabetic Gastroparesis (NASDAQ:TBPH)
www.streetinsider.com - December 6 at 7:45 PM
us.rd.yahoo.com logoTheravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis (NASDAQ:TBPH)
us.rd.yahoo.com - December 6 at 7:45 PM
News IconSorting Out the Technicals on Shares of Theravance Biopharma Inc. (TBPH) - StockTalk Daily (NASDAQ:TBPH)
stocktalkdaily.com - December 6 at 8:15 AM
us.rd.yahoo.com logo8:39 am Theravance Biopharma announces that GlaxoSmithKline (GSK (NASDAQ:TBPH)
us.rd.yahoo.com - December 5 at 7:52 PM
finance.yahoo.com logoTheravance Biopharma Highlights Filing of EU Regulatory Submission for the Closed Triple in COPD by GlaxoSmithKline and Innoviva (NASDAQ:TBPH)
finance.yahoo.com - December 5 at 8:48 AM
streetinsider.com logoTheravance Biopharma (TBPH) Affirms Filing of FF/UMEC/VI Submission with FDA for Use in COPD (NASDAQ:TBPH)
www.streetinsider.com - November 23 at 7:59 PM
marketexclusive.com logoHere's Our Take On Theravance Biopharma Inc (NASDAQ:TBPH ... - Market Exclusive (NASDAQ:TBPH)
marketexclusive.com - November 23 at 11:04 AM
marketexclusive.com logoHere's Our Take On Theravance Biopharma Inc (NASDAQ:TBPH) and GlaxoSmithKline plc (ADR) (NYSE:GSK)'s Latest ... - Market Exclusive (NASDAQ:TBPH)
marketexclusive.com - November 22 at 7:57 PM
finance.yahoo.com logoTheravance Biopharma to Present at the 28th Annual Piper Jaffray Healthcare Conference (NASDAQ:TBPH)
finance.yahoo.com - November 22 at 7:57 PM
insidermonkey.com logoHere's Our Take On Theravance Biopharma Inc (TBPH) And GlaxoSmithKline PLC (ADR) (GSK)'s Latest Submission - Insider Monkey (blog) (NASDAQ:TBPH)
www.insidermonkey.com - November 22 at 12:32 PM
streetinsider.com logoTheravance Biopharma (TBPH) Affirms Filing of FF/UMEC/VI Submission with FDA for Use in COPD - StreetInsider.com (NASDAQ:TBPH)
www.streetinsider.com - November 21 at 8:18 PM
finance.yahoo.com logoTHERAVANCE BIOPHARMA, INC. Financials (NASDAQ:TBPH)
finance.yahoo.com - November 17 at 7:29 PM
capitalcube.com logoETFs with exposure to Theravance Biopharma, Inc. : November 15, 2016 (NASDAQ:TBPH)
www.capitalcube.com - November 15 at 8:36 PM
biz.yahoo.com logoTHERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:TBPH)
biz.yahoo.com - November 14 at 7:59 PM
seekingalpha.com logoTheravance: Outperforming The Trump Rally - Seeking Alpha (NASDAQ:TBPH)
seekingalpha.com - November 14 at 12:01 PM
capitalcube.com logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : November 14, 2016 (NASDAQ:TBPH)
www.capitalcube.com - November 14 at 12:01 PM
capitalcube.com logoTheravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 (NASDAQ:TBPH)
www.capitalcube.com - November 14 at 12:01 PM

Social

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Where is Theravance Biopharma's stock going? Where will Theravance Biopharma's stock price be in 2017?

7 brokerages have issued 12-month price objectives for Theravance Biopharma's stock. Their forecasts range from $24.00 to $42.00. On average, they expect Theravance Biopharma's share price to reach $36.67 in the next year.

When will Theravance Biopharma announce their earnings?

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

What are analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:

  • According to Zacks Investment Research, "Theravance’s sole marketed product, Vibativ, continues to perform well, contributing meaningfully to the top line at the company. However, Vibativ witnessed a sequential decline due to seasonality and trends in surgical admissions. Nevertheless, the company’s efforts on the commercialization of Vibativ are encouraging. We are also positive on its efforts to expand the drug’s label, which if approved for additional indications, would be commercially significant. Further, its collaboration agreement with Mylan for revefenacin, a key late-stage pipeline candidate, is a big positive. Theravance’s progress with the rest of the pipeline is also impressive. Shares of the company have significantly outperformed the Medical-Drugs industry in 2016. Moreover, estimates have gone up ahead of the release of the company’s fourth-quarter 2016 results. However, Theravance’s heavy dependence on Vibativ for growth is concerning." (1/3/2017)

  • Leerink Swann analysts commented, "We reiterate our Outperform rating for Theravance’s stock. Stronger than expected Vibativ sales driven by a combination of new indication and expansion of dedicated sales force. Sales of Vibativ increased by 62% QoQ and 152% YoY apparently driven by the expansion of the sales force from 6 to 50 reps in 4Q15 and the opportunity presented by the expanded label. Mgmt believes the growth in revenue will continue driven by the expansion of accounts and positive physician perception in using Vibativ in difficult to treat patients. Several catalysts in next 12 months could potentially add additional value to the company. As highlighted in our earlier note [LINK], our sum of the parts analysis identified potential 20% and 70% upside by end of 2016 and 2017, respectively." (8/9/2016)

Who owns Theravance Biopharma stock?

Theravance Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.64%), Foundation Asset Management LP (0.98%), Marshall Wace LLP (0.79%), Franklin Resources Inc. (0.73%), Chescapmanager LLC (0.52%) and Royce & Associates LP (0.20%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham.

Who sold Theravance Biopharma stock? Who is selling Theravance Biopharma stock?

Theravance Biopharma's stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP. Company insiders that have sold Theravance Biopharma stock in the last year include Bradford J Shafer and Brett K Haumann.

Who bought Theravance Biopharma stock? Who is buying Theravance Biopharma stock?

Theravance Biopharma's stock was acquired by a variety of institutional investors in the last quarter, including Foundation Asset Management LP, Franklin Resources Inc., Marshall Wace LLP, Chescapmanager LLC, State Street Corp, Two Sigma Investments LP, Russell Investments Group Ltd. and Old West Investment Management LLC. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham.

How do I buy Theravance Biopharma stock?

Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Theravance Biopharma stock cost?

One share of Theravance Biopharma stock can currently be purchased for approximately $33.78.

Theravance Biopharma (NASDAQ:TBPH) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Earnings History Chart

Earnings by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Dividend History Chart

Dividend Payments by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Last Updated on 2/19/2017 by MarketBeat.com Staff